Taligen Therapeutics Adds $10 Mil. Tranche, Reveals Broad Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
The developer of therapies that act on the complement system expects to partner in ophthalmology while keeping its orphan disease program in-house.